PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33064187-9	2020	Strain with rAIP, GDH, DpkA, LysP, and DavB coexpression could produce delta-valerolactam.	2-piperidone	71-89	aryl-hydrocarbon receptor-interacting protein	Rattus norvegicus	12-16
26046940-7	2015	25-fold affinity improvement of the piperidinone family of inhibitors for MDM2 constructs that include the full lid correlates with interactions between ligand hydrophobic groups and the C-terminal lid region that is already partially ordered in apo MDM2.	2-piperidone	36-48	MDM2 proto-oncogene	Homo sapiens	74-78
28414905-6	2017	Upon coexpressing ORF26 with a metabolic pathway that produced 5-aminovaleric acid from lysine, we were able to demonstrate production of delta-valerolactam from lysine.	2-piperidone	138-156	hypothetical protein	Escherichia coli	18-23
30253242-0	2018	The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.	2-piperidone	19-32	MDM2 proto-oncogene	Homo sapiens	43-47
30253242-0	2018	The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.	2-piperidone	19-32	tumor protein p53	Homo sapiens	48-51
30253242-4	2018	This review is focused on the discovery and development of piperidinone-based MDM2-p53 inhibitors for cancer therapy, including the identification of hit compounds, hit-to-lead optimizations, binding models of ligands in the active site of MDM2, metabolic studies, and preclinical data of advanced piperidinone-based MDM2-p53 inhibitors.	2-piperidone	59-71	MDM2 proto-oncogene	Homo sapiens	78-82
30253242-4	2018	This review is focused on the discovery and development of piperidinone-based MDM2-p53 inhibitors for cancer therapy, including the identification of hit compounds, hit-to-lead optimizations, binding models of ligands in the active site of MDM2, metabolic studies, and preclinical data of advanced piperidinone-based MDM2-p53 inhibitors.	2-piperidone	59-71	tumor protein p53	Homo sapiens	83-86
30253242-4	2018	This review is focused on the discovery and development of piperidinone-based MDM2-p53 inhibitors for cancer therapy, including the identification of hit compounds, hit-to-lead optimizations, binding models of ligands in the active site of MDM2, metabolic studies, and preclinical data of advanced piperidinone-based MDM2-p53 inhibitors.	2-piperidone	59-71	MDM2 proto-oncogene	Homo sapiens	240-244
30253242-4	2018	This review is focused on the discovery and development of piperidinone-based MDM2-p53 inhibitors for cancer therapy, including the identification of hit compounds, hit-to-lead optimizations, binding models of ligands in the active site of MDM2, metabolic studies, and preclinical data of advanced piperidinone-based MDM2-p53 inhibitors.	2-piperidone	59-71	MDM2 proto-oncogene	Homo sapiens	240-244
30253242-4	2018	This review is focused on the discovery and development of piperidinone-based MDM2-p53 inhibitors for cancer therapy, including the identification of hit compounds, hit-to-lead optimizations, binding models of ligands in the active site of MDM2, metabolic studies, and preclinical data of advanced piperidinone-based MDM2-p53 inhibitors.	2-piperidone	59-71	tumor protein p53	Homo sapiens	322-325
30253242-4	2018	This review is focused on the discovery and development of piperidinone-based MDM2-p53 inhibitors for cancer therapy, including the identification of hit compounds, hit-to-lead optimizations, binding models of ligands in the active site of MDM2, metabolic studies, and preclinical data of advanced piperidinone-based MDM2-p53 inhibitors.	2-piperidone	298-310	MDM2 proto-oncogene	Homo sapiens	78-82
30253242-4	2018	This review is focused on the discovery and development of piperidinone-based MDM2-p53 inhibitors for cancer therapy, including the identification of hit compounds, hit-to-lead optimizations, binding models of ligands in the active site of MDM2, metabolic studies, and preclinical data of advanced piperidinone-based MDM2-p53 inhibitors.	2-piperidone	298-310	tumor protein p53	Homo sapiens	83-86
28669344-6	2018	Currently, nutlin, spirooxindole, isoquilinone and piperidinone analogues inhibiting p53-Mdm2 interaction are found to be promising in the treatment of cancer.	2-piperidone	51-63	transformation related protein 53, pseudogene	Mus musculus	85-88
28669344-6	2018	Currently, nutlin, spirooxindole, isoquilinone and piperidinone analogues inhibiting p53-Mdm2 interaction are found to be promising in the treatment of cancer.	2-piperidone	51-63	transformed mouse 3T3 cell double minute 2	Mus musculus	89-93
27150473-0	2016	Design and Synthesis of a Piperidinone Scaffold as an Analgesic through Kappa-Opioid Receptor: Structure-Activity Relationship Study of Matrine Alkaloids.	2-piperidone	26-38	opioid receptor kappa 1	Homo sapiens	72-93
26046940-7	2015	25-fold affinity improvement of the piperidinone family of inhibitors for MDM2 constructs that include the full lid correlates with interactions between ligand hydrophobic groups and the C-terminal lid region that is already partially ordered in apo MDM2.	2-piperidone	36-48	MDM2 proto-oncogene	Homo sapiens	250-254
25384157-1	2014	Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of cancer.	2-piperidone	132-144	MDM2 proto-oncogene	Homo sapiens	162-166
25522111-3	2015	Herein, we describe the spontaneous rearrangement of 4-carboxy-2-oxoazepane alpha,alpha-amino acids to lead to 2"-oxopiperidine-containing beta(2,3,3) -amino acids, upon basic or acid hydrolysis of the 2-oxoazepane alpha,alpha-amino acid ester.	2-piperidone	111-127	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	139-149
25384157-1	2014	Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of cancer.	2-piperidone	132-144	tumor protein p53	Homo sapiens	167-170
24601644-1	2014	We previously reported the discovery of potent and selective morpholinone and piperidinone inhibitors of the MDM2-p53 interaction.	2-piperidone	78-90	MDM2 proto-oncogene	Homo sapiens	109-113
25396040-5	2014	Soc., 2013, 135, 167 - 173) to a piperidinone-piperidine chemotype 1 indicated specific derivatives were candidates to perturb a protein-protein interface in the alpha-antithrombin dimer; those particular derivatives of 1 were prepared and tested.	2-piperidone	33-45	serpin family C member 1	Homo sapiens	168-180
25147610-0	2014	Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.	2-piperidone	35-47	MDM2 proto-oncogene	Rattus norvegicus	72-76
25147610-0	2014	Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.	2-piperidone	35-47	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	77-80
24858256-0	2014	Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.	2-piperidone	99-111	transformation related protein 53, pseudogene	Mus musculus	150-153
24858256-0	2014	Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.	2-piperidone	99-111	transformed mouse 3T3 cell double minute 2	Mus musculus	154-158
24858256-4	2014	In this study, a novel robust fragment-based QSAR model has been developed for piperidinone derived compounds experimentally known to inhibit p53-MDM2 interaction.	2-piperidone	79-91	transformation related protein 53, pseudogene	Mus musculus	142-145
24858256-4	2014	In this study, a novel robust fragment-based QSAR model has been developed for piperidinone derived compounds experimentally known to inhibit p53-MDM2 interaction.	2-piperidone	79-91	transformed mouse 3T3 cell double minute 2	Mus musculus	146-150
25042256-0	2014	Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.	2-piperidone	68-80	MDM2 proto-oncogene	Homo sapiens	118-122
25042256-0	2014	Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.	2-piperidone	68-80	tumor protein p53	Homo sapiens	123-126
25042256-1	2014	We recently reported on the discovery of AMG 232, a potent and selective piperidinone inhibitor of the MDM2-p53 interaction.	2-piperidone	73-85	MDM2 proto-oncogene	Homo sapiens	103-107
25042256-1	2014	We recently reported on the discovery of AMG 232, a potent and selective piperidinone inhibitor of the MDM2-p53 interaction.	2-piperidone	73-85	tumor protein p53	Homo sapiens	108-111
24967612-1	2014	We recently reported the discovery of AMG 232 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 protein-protein interaction.	2-piperidone	74-86	MDM2 proto-oncogene	Homo sapiens	104-108
24967612-1	2014	We recently reported the discovery of AMG 232 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 protein-protein interaction.	2-piperidone	74-86	tumor protein p53	Homo sapiens	109-112
24601644-1	2014	We previously reported the discovery of potent and selective morpholinone and piperidinone inhibitors of the MDM2-p53 interaction.	2-piperidone	78-90	tumor protein p53	Homo sapiens	114-117
24548297-1	2014	We previously reported the discovery of AMG 232, a highly potent and selective piperidinone inhibitor of the MDM2-p53 interaction.	2-piperidone	79-91	MDM2 proto-oncogene	Homo sapiens	109-113
24548297-1	2014	We previously reported the discovery of AMG 232, a highly potent and selective piperidinone inhibitor of the MDM2-p53 interaction.	2-piperidone	79-91	tumor protein p53	Homo sapiens	114-117
17367123-0	2007	Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.	2-piperidone	50-62	dipeptidyl peptidase 4	Homo sapiens	139-162
23811823-0	2013	Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping.	2-piperidone	18-30	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	49-55
23811823-5	2013	Subsequently, 2-piperidone was identified as a urinary metabolite that inversely correlated to the CYP2E1 activity in the three mouse lines.	2-piperidone	14-26	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	99-105
23811823-6	2013	Backcrossing of WT and Cyp2e1-null mice, together with targeted analysis of 2-piperidone in mouse serum, confirmed the genotype dependency of 2-piperidone.	2-piperidone	142-154	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	23-29
23811823-7	2013	The accumulation of 2-piperidone in the Cyp2e1-null mice was mainly caused by the changes in the biosynthesis and degradation of 2-piperidone because compared with the WT mice, the conversion of cadaverine to 2-piperidone was higher, whereas the metabolism of 2-piperidone to 6-hydroxy-2-piperidone was lower in the Cyp2e1-null mice.	2-piperidone	20-32	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	40-46
23811823-7	2013	The accumulation of 2-piperidone in the Cyp2e1-null mice was mainly caused by the changes in the biosynthesis and degradation of 2-piperidone because compared with the WT mice, the conversion of cadaverine to 2-piperidone was higher, whereas the metabolism of 2-piperidone to 6-hydroxy-2-piperidone was lower in the Cyp2e1-null mice.	2-piperidone	20-32	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	316-322
23811823-7	2013	The accumulation of 2-piperidone in the Cyp2e1-null mice was mainly caused by the changes in the biosynthesis and degradation of 2-piperidone because compared with the WT mice, the conversion of cadaverine to 2-piperidone was higher, whereas the metabolism of 2-piperidone to 6-hydroxy-2-piperidone was lower in the Cyp2e1-null mice.	2-piperidone	129-141	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	40-46
23811823-7	2013	The accumulation of 2-piperidone in the Cyp2e1-null mice was mainly caused by the changes in the biosynthesis and degradation of 2-piperidone because compared with the WT mice, the conversion of cadaverine to 2-piperidone was higher, whereas the metabolism of 2-piperidone to 6-hydroxy-2-piperidone was lower in the Cyp2e1-null mice.	2-piperidone	129-141	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	40-46
23811823-7	2013	The accumulation of 2-piperidone in the Cyp2e1-null mice was mainly caused by the changes in the biosynthesis and degradation of 2-piperidone because compared with the WT mice, the conversion of cadaverine to 2-piperidone was higher, whereas the metabolism of 2-piperidone to 6-hydroxy-2-piperidone was lower in the Cyp2e1-null mice.	2-piperidone	129-141	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	40-46
23811823-8	2013	Overall, untargeted metabolomic analysis identified a correlation between 2-piperidone concentrations in urine and the expression and activity of CYP2E1, thus providing a noninvasive metabolite biomarker that can be potentially used in to monitor CYP2E1 activity.	2-piperidone	74-86	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	146-152
23811823-8	2013	Overall, untargeted metabolomic analysis identified a correlation between 2-piperidone concentrations in urine and the expression and activity of CYP2E1, thus providing a noninvasive metabolite biomarker that can be potentially used in to monitor CYP2E1 activity.	2-piperidone	74-86	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	247-253
22524527-2	2012	The affinity of these compounds for MDM2 was improved through conformational control of both the piperidinone ring and the appended N-alkyl substituent.	2-piperidone	97-109	MDM2 proto-oncogene	Homo sapiens	36-40
24456472-1	2014	We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction.	2-piperidone	74-86	MDM2 proto-oncogene	Homo sapiens	104-108
24456472-1	2014	We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction.	2-piperidone	74-86	tumor protein p53	Homo sapiens	109-112
22991965-2	2012	Here, we present kinetic, thermodynamic, and structural rationale for the remarkable potency of a new class of MDM2 inhibitors, the piperidinones.	2-piperidone	132-145	MDM2 proto-oncogene	Homo sapiens	111-115
22991965-3	2012	While these compounds bind to the same site as previously reported for small molecule inhibitors, such as the Nutlins, data presented here demonstrate that the piperidinones also engage the N-terminal region (residues 10-16) of human MDM2, in particular, Val14 and Thr16.	2-piperidone	160-173	MDM2 proto-oncogene	Homo sapiens	234-238
22991965-4	2012	This portion of MDM2 is unstructured in both the apo form of the protein and in MDM2 complexes with p53 or Nutlin, but adopts a novel beta-strand structure when complexed with the piperidinones.	2-piperidone	180-193	MDM2 proto-oncogene	Homo sapiens	16-20
22991965-5	2012	The ordering of the N-terminus upon binding of the piperidinones extends the current model of MDM2-p53 interaction and provides a new route to rational design of superior inhibitors.	2-piperidone	51-64	MDM2 proto-oncogene	Homo sapiens	94-98
22991965-5	2012	The ordering of the N-terminus upon binding of the piperidinones extends the current model of MDM2-p53 interaction and provides a new route to rational design of superior inhibitors.	2-piperidone	51-64	tumor protein p53	Homo sapiens	99-102
22530559-1	2012	Chiral 2-piperidinone compounds with various C-6 substituents were successfully synthesized via a Pd-catalyzed asymmetric 6-endo cyclization of dienamides, which were evidently activated by both N-p-toluenesulfonyl and C-3 ester substituents.	2-piperidone	7-21	complement C6	Homo sapiens	45-48
22530559-1	2012	Chiral 2-piperidinone compounds with various C-6 substituents were successfully synthesized via a Pd-catalyzed asymmetric 6-endo cyclization of dienamides, which were evidently activated by both N-p-toluenesulfonyl and C-3 ester substituents.	2-piperidone	7-21	complement C3	Homo sapiens	219-222
15104472-2	2004	The one-pot tandem oxidation-cyclization-oxidation of unsaturated alcohols 1a-e by PCC or PCC and trifluoromethanesulfonic acid affords piperidinones 2a-e in good yield.	2-piperidone	136-149	crystallin gamma D	Homo sapiens	83-86
15863309-1	2005	Part 4: 2-Piperidones as selective EP4 receptor agonists.	2-piperidone	8-21	prostaglandin E receptor 4	Homo sapiens	35-38
15863309-4	2005	The 2-piperidones were identified as potent agonists at the EP4 prostanoid receptor.	2-piperidone	4-17	prostaglandin E receptor 4	Homo sapiens	60-63
15104472-2	2004	The one-pot tandem oxidation-cyclization-oxidation of unsaturated alcohols 1a-e by PCC or PCC and trifluoromethanesulfonic acid affords piperidinones 2a-e in good yield.	2-piperidone	136-149	crystallin gamma D	Homo sapiens	90-93
33548803-5	2021	This successfully led to the discovery of a piperidinone ring as a desirable motif at the indoline 5-position, which could minimize hERG liability as shown by 24b.	2-piperidone	44-56	ETS transcription factor ERG	Homo sapiens	132-136
6436440-1	1984	1-Piperideine, 5-aminopentanoic acid, and its lactam, 2-piperidone, were identified as metabolites of cadaverine in 10,000 g mouse liver supernatants to which diamine oxidase had been added.	2-piperidone	54-66	amine oxidase, copper-containing 1	Mus musculus	159-174